Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy

BACKGROUND: The 2018 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends combination long-acting muscarinic antagonists/long-acting beta2-agonists (LAMA + LABA) as preferred maintenance therapy for patients with symptomatic chronic obstructive lung disease (COPD) after monothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Palli, Swetha R., Frazer, Monica, DuCharme, Mary, Buikema, Ami R., Anderson, Amy J., Franchino-Elder, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390943/
https://www.ncbi.nlm.nih.gov/pubmed/32678719
http://dx.doi.org/10.18553/jmcp.2020.20159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390943/
https://www.ncbi.nlm.nih.gov/pubmed/32678719
http://dx.doi.org/10.18553/jmcp.2020.20159

Ejemplares similares